In conclusion, our current work demonstrated a selective targeting of PP2Aa-STRN3 or STRN3-MST1/2 by the FDA-approved drugs to restore and even enhance the Hippo signal, which not only directly inhibit GC growth but also sensitize GC to chemotherapy. This evidence concerns the gene MST1 and gastric cancer.